5X8L
 
 | | PD-L1 in complex with atezolizumab | | 分子名称: | Programmed cell death 1 ligand 1, atezolizumab heavy chain, atezolizumab light chain | | 著者 | Heo, Y.S, Lee, H.T. | | 登録日 | 2017-03-03 | | 公開日 | 2017-08-16 | | 実験手法 | X-RAY DIFFRACTION (3.1 Å) | | 主引用文献 | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Sci Rep, 7, 2017
|
|
5Y9J
 | | BAFF in complex with belimumab | | 分子名称: | Tumor necrosis factor ligand superfamily member 13B, belibumab light chain, belimumab heavy chain | | 著者 | Heo, Y.-S, Shin, W. | | 登録日 | 2017-08-25 | | 公開日 | 2018-02-21 | | 最終更新日 | 2019-09-04 | | 実験手法 | X-RAY DIFFRACTION (2.05 Å) | | 主引用文献 | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
5Y9K
 | | Structure of the belimumab Fab fragment | | 分子名称: | belimumab heavy chain, belimumab light chain | | 著者 | Heo, Y.-S, Shin, W. | | 登録日 | 2017-08-25 | | 公開日 | 2018-02-21 | | 最終更新日 | 2019-09-04 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
1IZ3
 | | Dimeric structure of FIH (Factor inhibiting HIF) | | 分子名称: | FIH, SULFATE ION | | 著者 | Lee, C, Kim, S.-J, Jeong, D.-G, Lee, S.M, Ryu, S.-E. | | 登録日 | 2002-09-19 | | 公開日 | 2003-06-10 | | 最終更新日 | 2023-12-27 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau.
J.Biol.Chem., 278, 2003
|
|
1I7F
 | | CRYSTAL STRUCTURE OF THE HSP33 DOMAIN WITH CONSTITUTIVE CHAPERONE ACTIVITY | | 分子名称: | GLYCEROL, HEAT SHOCK PROTEIN 33, SULFATE ION | | 著者 | Kim, S.-J, Jeong, D.-G, Chi, S.-W, Lee, J.-S, Ryu, S.-E. | | 登録日 | 2001-03-09 | | 公開日 | 2001-05-09 | | 最終更新日 | 2021-10-27 | | 実験手法 | X-RAY DIFFRACTION (2.7 Å) | | 主引用文献 | Crystal structure of proteolytic fragments of the redox-sensitive Hsp33 with constitutive chaperone activity
Nat.Struct.Biol., 8, 2001
|
|
1KU0
 | | Structure of the Bacillus stearothermophilus L1 lipase | | 分子名称: | CALCIUM ION, L1 lipase, ZINC ION | | 著者 | Jeong, S.-T, Kim, H.-K, Kim, S.-J, Chi, S.-W, Pan, J.-G, Oh, T.-K, Ryu, S.-E. | | 登録日 | 2002-01-18 | | 公開日 | 2002-08-21 | | 最終更新日 | 2024-03-13 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Novel zinc-binding center and a temperature switch in the Bacillus stearothermophilus L1 lipase.
J.Biol.Chem., 277, 2002
|
|
5GGU
 | | Crystal structure of tremelimumab Fab | | 分子名称: | heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (2.292 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGS
 | | PD-1 in complex with pembrolizumab Fab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.997 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGV
 | | CTLA-4 in complex with tremelimumab Fab | | 分子名称: | Cytotoxic T-lymphocyte protein 4, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.998 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGT
 | | PD-L1 in complex with BMS-936559 Fab | | 分子名称: | IGK@ protein, IgG H chain, Programmed cell death 1 ligand 1 | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2024-03-20 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGR
 | | PD-1 in complex with nivolumab Fab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (3.3 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGQ
 | | Crystal structure of Nivolumab Fab fragment | | 分子名称: | nivolumab heavy chain, nivolumab light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
2ORY
 | |
6KEI
 | | Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 16-methoxy-11-methyl-6-[(pyridin-2-yl)methoxy]-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(16),3,5,7,9,13(17),14-heptaen-12-one | | 分子名称: | 16-methoxy-11-methyl-6-[(pyridin-2-yl)methoxy]-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(16),3,5,7,9,13(17),14-heptaen-12-one, Bromodomain-containing protein 4, FORMIC ACID | | 著者 | Lee, B.I, Park, T.H. | | 登録日 | 2019-07-04 | | 公開日 | 2020-07-08 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (1.451 Å) | | 主引用文献 | Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.
Molecules, 26, 2021
|
|
6LYF
 | |
6M3T
 | |
6M3F
 | |
6KEC
 | | Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 4-ethoxy-5,16-dimethoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(17),3,5,7,9,13,15-heptaen-12-one | | 分子名称: | 4-ethoxy-5,16-dimethoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(17),3,5,7,9,13,15-heptaen-12-one, Bromodomain-containing protein 4, FORMIC ACID | | 著者 | Lee, B.I, Park, T.H. | | 登録日 | 2019-07-04 | | 公開日 | 2020-07-08 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (1.35 Å) | | 主引用文献 | Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.
Molecules, 26, 2021
|
|
6KEH
 | | Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 6,16-dimethoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(17),3,5,7,9,13,15-heptaen-12-one | | 分子名称: | 6,16-dimethoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(17),3,5,7,9,13,15-heptaen-12-one, Bromodomain-containing protein 4, FORMIC ACID | | 著者 | Lee, B.I, Park, T.H. | | 登録日 | 2019-07-04 | | 公開日 | 2020-07-08 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (1.553 Å) | | 主引用文献 | Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.
Molecules, 26, 2021
|
|
6KEK
 | | Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 6-hydroxy-16-methoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(16),3,5,7,9,13(17),14-heptaen-12-one | | 分子名称: | 6-hydroxy-16-methoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(16),3,5,7,9,13(17),14-heptaen-12-one, Bromodomain-containing protein 4, FORMIC ACID | | 著者 | Lee, B.I, Park, T.H. | | 登録日 | 2019-07-04 | | 公開日 | 2020-07-08 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (1.553 Å) | | 主引用文献 | Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.
Molecules, 26, 2021
|
|
6KEJ
 | | Crystal structure of BRD4 bromodomain 1 (BD1) in complex with 6-[2-(diethylamino)ethoxy]-16-methoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(17),3,5,7,9,13,15-heptaen-12-one | | 分子名称: | 6-[2-(diethylamino)ethoxy]-16-methoxy-11-methyl-2-oxa-11-azatetracyclo[8.6.1.03,8.013,17]heptadeca-1(17),3,5,7,9,13,15-heptaen-12-one, Bromodomain-containing protein 4, FORMIC ACID | | 著者 | Lee, B.I, Park, T.H. | | 登録日 | 2019-07-04 | | 公開日 | 2020-07-08 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (1.85 Å) | | 主引用文献 | Synthesis and Structure-Activity Relationships of Aristoyagonine Derivatives as Brd4 Bromodomain Inhibitors with X-ray Co-Crystal Research.
Molecules, 26, 2021
|
|
